<DOC>
	<DOCNO>NCT02410512</DOCNO>
	<brief_summary>This Phase Ib , open-label , dose-escalation study evaluate safety , tolerability , pharmacokinetics combination MOXR0916 Atezolizumab without bevacizumab participant locally advance , recurrent , metastatic incurable solid malignancy progress available standard therapy , standard therapy proven ineffective intolerable , consider inappropriate ; clinical trial investigational agent recognize standard care .</brief_summary>
	<brief_title>A Dose-Escalation Study Safety Pharmacokinetics MOXR0916 Atezolizumab With Without Bevacizumab Participants With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Patients 18 year age old Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 12 week Adequate hematologic end organ function Histologic documentation locally advance , recurrent metastatic incurable solid malignancy progress available standard therapy , standard therapy ineffective , intolerable , consider inappropriate ; clinical trial investigational agent recognize standard care Tumor specimen availability Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST v1.1 ) Any anticancer therapy , whether investigational approve , include chemotherapy , hormonal therapy , radiotherapy , within 3 week prior initiation study treatment Malignancies disease study within 5 year prior Cycle 1 , Day 1 Primary central nervous system ( CNS ) malignancy , untreated/active CNS metastase Leptomeningeal disease History idiopathic pulmonary fibrosis , pneumonitis ( include drug induce ) , organize pneumonia , evidence active pneumonitis screen chest compute tomography ( CT ) scan ; history radiation pneumonitis radiation field ( fibrosis ) permit History autoimmune disease Positive human immunodeficiency virus ( HIV ) test Active hepatitis B C , tuberculosis Severe infection within 4 week prior randomization Prior allogenic bone marrow solid organ transplantation Significant cardiovascular disease Known clinically significant liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>